Transcatheter Cardiovascular Therapeutics Conference 2005 In Brief
This article was originally published in The Gray Sheet
Executive Summary
St. Jude's Proxis: 600-patient, 67-site PROXIMAL trial of embolic protection in saphenous vein grafts shows that the Proxis proximal protection device is associated with fewer major adverse cardiac events than Boston Scientific's FilterWire or Medtronic's GuardWire distal protection devices, according to investigator Campbell Rogers, MD, Brigham & Women's Hospital, Boston. The Proxis group had a 7.1% MACE rate compared to 10.2% for distal protection, and patients were 60% less likely to experience a MACE with Proxis than with the distal devices. David Holmes, MD, Mayo Clinic, who critiqued the presentation at TCT on Oct. 18, noted that for this device, "the fine print is going to be incredibly important," but that he is confident Proxis would be very effective in the hands of experienced investigators...